Sunday, 22 July 2018 - 15:51
  • it
  • de
  • en
  • fr

Keytruda

Why Merck & Co. makes serious bet on Keytruda

The US-based group Merck & Co. is largely focusing on its blockbuster Keytruda, an immunotherapy launched in Q4 2014 that has delivered approximately $5bn revenues since then, $3.8bn of which in 2017, that is as much as 9% of the…

Rude awakening for immunotherapy sector

Last Friday’s news about the failed Phase III clinical trial with immunotherapy Keytruda in combination with Incyte’s cancer therapy epacadostat not only has wiped $4m from the US biotech’s capitalization over few hours, but has also risen much concern among…

The immunotherapy market

The Financial Times has published  today a very short review about the immunotherapy market. This business is currently dominated by Merck & Co and Bristol-Myers Squibb with blockbusters Keytruda and Opdivo, however these are already facing competition from Roche, Pfizer…

Merck & Co. signs multi-billion agreement with Eisai on Keytruda

US-based pharmaceutical group Merck & Co has entered into an agreement with Japan-based  Eisai Co aimed at further developing and, subsequently, marketing cancer drug Lenvima (lenvatinib), a treatment discovered by Eisai which has already been approved for a dozen cancer…

New strategic move by BMS: collaboration with Infinity Pharmaceuticals expanded

Bristol-Myers Squibb and Cambridge, US-based biotech company Infinity Pharmaceuticals announced they have expanded the cooperation agreement aimed at evaluating Infinity’s IPI-549 in combination with Opdivo (nivolumab) to include patients with triple negative breast cancer (TNBC). TNBC has shown resistance to…

Research on new cancer therapies: state of the art

The Economist has chosen the state of the art of cancer therapies as the latest Technology Quarterly’s topic. Cancer kills 8.8m people each year and affects at least one on three people in western countries. Although this death rate is…

Immunotherapy takes risky gamble

Many analysts believe there is excessive enthusiasm in the pharmaceutical market about immunotherapies for cancer. Merck & Co. and Bristol-Myers Squibb lead the industry until now, with their respective immunotherapies Keytruda and Opdivo, both “checkpoint inhibitors”, generating together over $4bn…

What future for immuno-oncology?

On the eve of the American Society of Clinical Oncology annual meeting, pharmaceutical industry analysts are wondering what is the future of immuno-oncology. Few treatment areas, indeed, have seen so many changes and innovations as oncology over such a short…

Keytruda: first drug approved in US for biomarker-based cancers

FDA has approved for the first time a drug for the treatment of tumors based on a biomarker rather than the location in the body where they originated. The drug is MSD’s Keytruda (pembrolizumab), which was granted approval, by priority…

European Commission approves MSD’s Keytruda for Hodgkin Lymphoma

MSD announced that the European Commission approved Keytruda (pembrolizumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin, or who are transplant-ineligible. The approved…

FDA accepts two sBLAs for MSD’s Keytruda

MSD announced that FDA has granted Priority Review for two sBLAs (supplemental Biologics License Application) for Keytruda (pembrolizumab), an anti-PD-1 treatment for patients with metastatic or locally advanced urothelial carcinoma. The sBLAs refer to the use of the product as…

MSD’s Keytruda, FDA accepts sBLA with Priority Review for new indication

MSD announced today that FDA accepted a sBLA (supplemental Biologics License Application) for Keytruda (pembrolizumab) for the treatment of previously treated patients with MSI-H cancer (microsatellite instability-high). The PDUFA, with Priority Review, is scheduled for early March 2017 and will…

The immunotherapy market

Analysts estimate the value of the cancer immunotherapy market to achieve soon $35bn pa. To date, only three multinationals have succeeded in launching an immunotherapy on the market—Bristol-Myers Squibb with Opdivo, MSD with Keytruda and Roche, which launched Tecentriq in…

MSD’s Keytruda meets endpoint and trial stops early

MSD announced that the Phase III KEYNOTE-045 trial, designed to assess Keytruda (pembrolizumab), in patients with previously treated urothelial cancer, has been discontinued early following an independent Data Monitoring Committee evaluation, since the trial met the primary endpoint of overall…

Highlights of ESMO 2016

The year’s most anticipated results in the oncological field were expected at the European Society for Medical Oncology (ESMO) Annual Congress. Many comments focused on lung cancer. MSD reported that Keytruda reduces the risk of disease progression by 50% and…

Very positive results for MSD’s Keytruda in NSCLC

MSD announced at the ESMO annual congress the results from Keynote-024, a trial investigating the use of Keytruda (pembrolizumab) vs chemotherapy in patients with NSCLC (non-small cell lung cancer). Keytruda reduced the risk of disease progression or death by 50%…